Overview

Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate